These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 8069863)

  • 1. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS; Danks MK; Granzen B; Beck WT
    Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation.
    Su ZZ; Yemul S; Stein CA; Fisher PB
    Oncogene; 1995 May; 10(10):2037-49. PubMed ID: 7761104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
    Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
    Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired induction of c-fos/c-jun genes and of transcriptional regulatory proteins binding distinct c-fos/c-jun promoter elements in activated human T cells during aging.
    Whisler RL; Chen M; Beiqing L; Carle KW
    Cell Immunol; 1997 Jan; 175(1):41-50. PubMed ID: 9015187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of c-jun expression during induction of monocytic differentiation by okadaic acid.
    Kharbanda S; Datta R; Rubin E; Nakamura T; Hass R; Kufe D
    Cell Growth Differ; 1992 Jul; 3(7):391-9. PubMed ID: 1419903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation and inhibition of the AP-1 complex in human breast cancer cells.
    Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
    Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription factor c-Jun activation represses mdr-1 gene expression.
    Miao ZH; Ding J
    Cancer Res; 2003 Aug; 63(15):4527-32. PubMed ID: 12907627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
    Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
    Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
    Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinate regulation of glucocorticoid receptor and c-jun gene expression is cell type-specific and exhibits differential hormonal sensitivity for down- and up-regulation.
    Barrett TJ; Vig E; Vedeckis WV
    Biochemistry; 1996 Jul; 35(30):9746-53. PubMed ID: 8703946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.